Momo Inc. (MOMO) shares are trading at 41.20, up 5%. The company is reporting earnings on Wednesday, August 22. What's driving MOMO stock price? What's MOMO stock price 'forecast'? Momo is a popular Chinese mobile dating and social networking company with a fast and profitable growth, strong track record, and a huge addressable market. Its market cap is $8...
First of all, let's note that healthcare and biotech stocks have been a subject to a broad selloff, some more than others. The SPDR S&P Biotech ETF (XBI) has declined more than the major indexes. The bulls say this is a great opportunity to buy Sorrento, citing a reasonable price for a solid, growth stock. Among the near-term catalysts that can boost the stock...
Ability Inc. (ABIL) shares are trading at 4.65, ahead of earnings next week. The ABIL stock price skyrocketed on August 8, when the shares price more than doubled. Previously, the stock popped on June 26 and gained more than 5x in value. What's ABIL stock price forecast? First, some background on the company. Ability Inc. provides interception, geolocation,...
The company reported earnings on August 14. Q2 net revenues were $16.46 million, an increase of 2% compared to the second quarter of 2017 driven by organic growth of the transaction solutions segment. International transaction solutions segment experienced a decline of 19%. The company is not profitable; it generates an EPS of -22 cents per share. Last...
YY is a social media and internet streaming company based in the People's Republic of China. The company has an appealing quality and growth outlook, given that access to internet services in China has improved in the recent years and it is still on the upside. The company produced solid Q2 numbers; however, it issued low Q3 guidance, and as a result, the...
Actinium is a small biopharma firm that develops targeted payload immunotherapeutics for the treatment of advanced cancers. The company's technology utilizes monoclonal antibodies to deliver radioisotopes directly to cells of interest in order to kill those cells safely and effectively. Its lead product candidate is Iomab-B that is in Phase III clinical studies in...
PowerShares QQQ is a top U.S. - Large Cap Growth fund by assets and is hugely popular among individual investors. We’ll cover some of the basic and advanced topics you should know about QQQ, such as: www.finstead.com QQQ ETF profile QQQ underlying index (i.e., what does it track?) QQQ holdings QQQ historical performance QQQ dividend yield QQQ expense ratio QQQ...
First, some background on NEO: it is the 13th largest coin by market cap ($1.48 billion). In order to enhance security for its blockchain and smart contract technologies, NEO is exploring various solutions. It has partnered with a formal verification platform for smart contracts and blocks chain ecosystems, known as Certik. Coinbase is exploring the option to...
Ripple (XRP.X) is trading at $0.35, up 6% from yesterday. Ripple's price is forming a strong support base near $0.327 level against the US Dollar. What is Ripple's price forecast? Is it finally rebounding? First, here are some fundamentals about Ripple. It is different from other crypto companies because it sells services to financial institutions. Ripple...
While Novavax has some positives, it is not a good candidate for new money. Novavax's two marquee programs, RSV F for maternal vaccination and NanoFlu are not doing particularly well, as they are getting delayed. RSV F for maternal vaccination is now in Phase 3, but many investors are wondering if it's a viable drug. Even if Novavax successfully meets the...
22nd Century Group is a little biotech developing technology which allows the increase or decrease in the level of nicotine and other nicotinic alkaloids in tobacco plants. The company also has the technology to control levels of cannabinoids in cannabis plants. The shares have appreciated lately, which is a normal occurrence for a news-driven stock. XXII has...
There are some positive commercial developments for the company. The mega-insurer Cigna stated it will cover ThyraMIR, a microRNA gene expression classifier for thyroid nodules, that Interpace Diagnostics developed. The health insurer has covered another IDXG's drug ThyGenX since 2017. 80% of ThyGenX orders are coupled with an order for ThyraMIR, and the two...
On July 24, the shares of the company plunged in reaction to a negative patent ruling involving litigation between Nevro and Boston Scientific that occurred just before the closing bell. Before the bell on the next day, the shares were buoyed by district court rulings. The court "ruled in favor of Nevro regarding six method claims in three of its patents, finding...
The shares of small oncology company rallied over 50% since mid-May, because the company's first product is likely to be approved by the FDA in October. The stock has garnered analyst interest as of lately. Verastem took advantages of the rise in share price to announce a secondary offering priced at $4.50 a share. www.finstead.com
NXPI share price plunged following a failed merger with Qualcomm. Many investors believe that the current market price significantly undervalues NXPI shares, so the company commenced on a significant buyback. Following the deal termination, many analysts have issued price targets substantially higher than the current NXPI share price, and upgraded the stock to...
NII Holdings (NIHD) operates telecom services in Brazil under the Nextel brand. NII is the controlling owner of Nextel Brazil after its partner ICE.net failed to increase its stake in the entity. The shares of this Brazilian telecom provider have doubled since early June. The company made significant improvements on many fronts, but it still bleeds cash and has...
Bitcoin fell sharply on Wednesday because the SEC postponed its decision on whether it would approve a bitcoin exchange-traded fund (ETF) proposed by VanEck and SolidX. This is VanEck's third attempt to push a Bitcoin ETF through. However, some investors claim the price fall is just a minor correction. Brian Kelly, the CEO of the digital currency investment firm...
Just yesterday Neovasc resolved potential legal claims that could be brought against the company with the University of Pennsylvania (a.k.a. Penn). The firm has signed a collaboration and licensing agreement with Penn's Gorman Cardiovascular Research Group. Based on the agreement, for a period of time over the next four years Neovasc will pay a fee to Penn. The...